Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMP1734 · 1 trial · 1 indication
Number of subjects reporting adverse events or serious adverse events which include any abnormal clinical events, laboratory assessments outside of normal clinical range, abnormal vital signs observed, and any abnormal ECG parameters
Number of patients that experience a DLT or any toxicity which occurs from the time of the first dose of study drug until the end of cycle 1, which is deemed unrelated to the disease.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | IMP1734 monotherapy; oral tablet(s) daily (except for the single-dose period). The maximum trial duration is 3 years after the last participant's first treatment in the trial. |
| Name | Type | Description |
|---|---|---|
| IMP1734 | DRUG | PARP1 selective inhibitor |
Key Inclusion Criteria * Breast cancer; must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy if HR+, * HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one pri...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
IMP1734 is an investigational small molecule developed by Eikon Therapeutics, Inc. for the treatment of advanced solid tumors. It is a PARP1 selective inhibitor and is currently in Phase 1 clinical development. The drug is being evaluated in a first-in-human study and has not been approved by the FDA.
IMP1734 is being studied for the treatment of advanced solid tumors. It is an investigational therapy in Phase 1 development and is not approved for any indication. The ongoing trial enrolls adults with advanced solid tumors and includes biomarker-selected participants.
IMP1734 targets PARP1, a protein involved in DNA repair. By selectively inhibiting PARP1, the drug is designed to interfere with DNA repair processes in tumor cells. This PARP1 selective mechanism distinguishes it from broader PARP inhibitors and is the basis for its evaluation in advanced solid tumors.
IMP1734 is being developed by Eikon Therapeutics, Inc., which trades under the ticker EIKN. The company is running the first-in-human Phase 1 study of the PARP1 selective inhibitor in participants with advanced solid tumors across multiple countries.
IMP1734 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The single ongoing trial is a first-in-human study that is currently recruiting participants with advanced solid tumors.
IMP1734 is being evaluated in one clinical trial, NCT06253130, titled A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors. The Phase 1 trial is recruiting and plans to enroll 156 participants across the United States, Australia, Canada, China, Denmark, France, South Korea, and Spain.